WO2003085096A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2003085096A3
WO2003085096A3 PCT/US2003/009929 US0309929W WO03085096A3 WO 2003085096 A3 WO2003085096 A3 WO 2003085096A3 US 0309929 W US0309929 W US 0309929W WO 03085096 A3 WO03085096 A3 WO 03085096A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
methods
polypeptide
acids encoding
encoding same
Prior art date
Application number
PCT/US2003/009929
Other languages
French (fr)
Other versions
WO2003085096A2 (en
Inventor
John P Ii Alsobrook
David W Anderson
Ferenc L Boldog
Catherine E Burgess
Stacie J Casman
Original Assignee
Curagen Corp
John P Ii Alsobrook
David W Anderson
Ferenc L Boldog
Catherine E Burgess
Stacie J Casman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/403,676 external-priority patent/US20040029150A1/en
Application filed by Curagen Corp, John P Ii Alsobrook, David W Anderson, Ferenc L Boldog, Catherine E Burgess, Stacie J Casman filed Critical Curagen Corp
Priority to AU2003230775A priority Critical patent/AU2003230775A1/en
Priority to EP03723868A priority patent/EP1622634A2/en
Priority to CA002481039A priority patent/CA2481039A1/en
Publication of WO2003085096A2 publication Critical patent/WO2003085096A2/en
Publication of WO2003085096A3 publication Critical patent/WO2003085096A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
PCT/US2003/009929 2002-04-01 2003-04-01 Therapeutic polypeptides, nucleic acids encoding same, and methods of use WO2003085096A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003230775A AU2003230775A1 (en) 2002-04-01 2003-04-01 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP03723868A EP1622634A2 (en) 2002-04-01 2003-04-01 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA002481039A CA2481039A1 (en) 2002-04-01 2003-04-01 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US36899602P 2002-04-01 2002-04-01
US60/368,996 2002-04-01
US36998002P 2002-04-04 2002-04-04
US60/369,980 2002-04-04
US37038102P 2002-04-05 2002-04-05
US60/370,381 2002-04-05
US37096902P 2002-04-08 2002-04-08
US60/370,969 2002-04-08
US37100202P 2002-04-09 2002-04-09
US60/371,002 2002-04-09
US37200202P 2002-04-12 2002-04-12
US60/372,002 2002-04-12
US38429702P 2002-05-30 2002-05-30
US60/384,297 2002-05-30
US38681602P 2002-06-07 2002-06-07
US60/386,816 2002-06-07
US38912302P 2002-06-13 2002-06-13
US60/389,123 2002-06-13
US40220702P 2002-08-09 2002-08-09
US60/402,207 2002-08-09
US42086002P 2002-10-24 2002-10-24
US60/420,860 2002-10-24
US10/403,676 US20040029150A1 (en) 1999-03-09 2003-03-31 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US10/403,676 2003-03-31

Publications (2)

Publication Number Publication Date
WO2003085096A2 WO2003085096A2 (en) 2003-10-16
WO2003085096A3 true WO2003085096A3 (en) 2004-09-23

Family

ID=28795498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009929 WO2003085096A2 (en) 2002-04-01 2003-04-01 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (4)

Country Link
EP (1) EP1622634A2 (en)
AU (1) AU2003230775A1 (en)
CA (1) CA2481039A1 (en)
WO (1) WO2003085096A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003102584A2 (en) * 2002-05-30 2003-12-11 Curagen Corporation Semaphorin-like proteins and methods of using same
EP2691107A4 (en) * 2011-03-30 2014-11-05 Univ Manitoba 2 Methods for using semaphorin polypeptides
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042285A2 (en) * 1999-12-10 2001-06-14 Incyte Genomics, Inc. Extracellular matrix and cell adhesion proteins as well as genes encoding them
WO2002006339A2 (en) * 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
WO2003003984A2 (en) * 2001-07-05 2003-01-16 Curagen Corporation Novel proteins and nucleic acids encoding same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042285A2 (en) * 1999-12-10 2001-06-14 Incyte Genomics, Inc. Extracellular matrix and cell adhesion proteins as well as genes encoding them
WO2002006339A2 (en) * 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
WO2003003984A2 (en) * 2001-07-05 2003-01-16 Curagen Corporation Novel proteins and nucleic acids encoding same

Also Published As

Publication number Publication date
AU2003230775A1 (en) 2003-10-20
EP1622634A2 (en) 2006-02-08
CA2481039A1 (en) 2003-10-16
WO2003085096A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002064791A3 (en) Proteins and nucleic acids encoding same
WO2002050277A3 (en) Protein and nucleic acids encoding same
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2002057450A3 (en) Proteins and nucleic acids encoding same
WO2002081518A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002098917A3 (en) Human proteins and nucleic acids encoding same
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2002029038A3 (en) Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002010216A3 (en) Proteins and nucleic acids encoding same
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2002046229A3 (en) Novel proteins and nucleic acids encoding same
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002099116A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003085124A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002083841A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001025436A3 (en) Endozepine-like polypeptides and polynucleotides encoding same
WO2001094416A3 (en) Human proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003230775

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2481039

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003723868

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003723868

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003723868

Country of ref document: EP